Reslizumab, an investigational humanized monoclonal antibody from Teva Pharmaceuticals, appears to cut the risk of severe asthma attacks in half for patients who have difficulty controlling the disorder with standard medications, according to results published in Lancet Respiratory Medicine.

“The drug, reslizumab, reduces asthma attacks in a particular population of patients,” said principal investigator Mario Castro, MD, the Alan A. and Edith L. Wolff Professor of Pulmonary and Critical Care Medicine at Washington University School of Medicine in St. Louis. “It helped prevent severe attacks that typically require patients to contact their physicians and that usually result in those patients being placed on oral steroids that come with a range of side effects.”